Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Severe Parkinsonism and Creatine Kinase Increase After Low-Dose Aripiprazole Treatment in a Patient of African Descent

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Off-Label Prescription of Psychopharmacological Drugs in Child and Adolescent Psychiatry

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Norquetiapine and Depressive Symptoms in Initially Antipsychotic-Naive First-Episode Schizophrenia

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Augmenting Clozapine With Sertindole: A Double-Blind, Randomized, Placebo-Controlled Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Reappraisal is an effective emotion regulation strategy in children with Tourette syndrome and ADHD

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Biographical disruption or cohesion? How parents deal with their child's autism diagnosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Correction to: Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Aripiprazole is a partial dopamine agonist with only minor neurological and psychiatric adverse effects, making it a potential first-line drug for the treatment of psychiatric disorders. However, the evidence of its use in children and adolescents is rather sparse. The aim of this case study is to discuss adverse drug reaction (ADR) reports concerning aripiprazole-associated neurological and psychiatric events in children and adolescents. The ADR report database at Danish Medicines Agency was searched for all ADRs involving children and adolescents (<18 years) reported by the search term [aripiprazole] AND all spontaneous reports since the introduction of aripiprazole in 2003 until December 31, 2015. Nineteen case reports were included in the study and included both patients with psychotic disorders (PS group) and nonpsychotic disorders (non-PS group). The PS group consisted of 5 patients with schizophrenia and psychoses, not otherwise specified; and the non-PS group consisted of fourteen cases including autism spectrum disorders, attention deficit and hyperactivity disorder, obsessive-compulsive disorder, and Tourette syndrome. The main reported adverse effects in the non-PS group were chronic insomnia, Parkinsonism, behavioral changes psychoses, and weight gain, whereas the adverse effects in the PS group was predominantly anxiety, convulsions, and neuroleptic malignant syndrome. Although aripiprazole is considered safe and well tolerated in children and adolescents, severe adverse events as neuroleptic malignant syndrome, extreme insomnia, and suicidal behavior has been reported to health authorities. Clinicians should pay attention to these possible hazards when prescribing aripiprazole to this vulnerable group of patients.

Original languageEnglish
JournalJournal of Clinical Psychopharmacology
Volume36
Issue number5
Pages (from-to)496-9
Number of pages3
ISSN0271-0749
DOIs
Publication statusPublished - Oct 2016

ID: 48332750